China Shineway Pharmaceutical Group Limited Capital Reinvestment Ratio
China Shineway Pharmaceutical Group Limited capital reinvestment ratio. China Shineway Pharmaceutical Group Limited (C1S) has a Capital Reinvestment Ratio of 0.15x as of June 2023, meaning it reinvests 0% of its operating cash flow (€160.69 Million) in capital expenditures (€24.57 Million). Check China Shineway Pharmaceutical Group Limi (C1S) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of China Shineway Pharmaceutical Group Limited (2013–2025)
Capital reinvestment ratio of China Shineway Pharmaceutical Group Limited from 2013 to 2025. This chart tracks China Shineway Pharmaceutical Group Limited's Capital Reinvestment Ratio across 13 annual periods. Also explore C1S net asset momentum to track the company's year-over-year net asset growth rate.
China Shineway Pharmaceutical Group Limited Capital Reinvestment Ratio by Year (2013–2025)
China Shineway Pharmaceutical Group Limited capital reinvestment ratio by year from 2013 to 2025. For the full cash flow conversion analysis, see China Shineway Pharmaceutical Group Limi (C1S) cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.17x | €1.17 Billion | €197.91 Million | ▲ +16.1% |
| 2024 | 0.15x | €963.13 Million | €140.11 Million | ▼ -6.0% |
| 2023 | 0.15x | €932.63 Million | €144.32 Million | ▲ +32.6% |
| 2022 | 0.12x | €1.11 Billion | €129.46 Million | ▼ -12.4% |
| 2021 | 0.13x | €703.15 Million | €93.63 Million | ▲ +28.8% |
| 2020 | 0.10x | €638.57 Million | €66.03 Million | ▼ -57.0% |
| 2019 | 0.24x | €368.00 Million | €88.40 Million | ▲ +0.5% |
| 2018 | 0.24x | €532.59 Million | €127.34 Million | ▲ +27.8% |
| 2017 | 0.19x | €490.65 Million | €91.83 Million | ▲ +28.5% |
| 2016 | 0.15x | €733.53 Million | €106.79 Million | ▲ +1.7% |
| 2015 | 0.14x | €744.71 Million | €106.56 Million | ▲ +6.2% |
| 2014 | 0.13x | €773.16 Million | €104.18 Million | ▼ -73.3% |
| 2013 | 0.50x | €519.89 Million | €261.89 Million | — |